

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



国药集团
SINOPHARM

國藥控股股份有限公司 SINOPHARM GROUP CO. LTD.*

(A joint stock limited company incorporated in the People's Republic of China with limited liability and carrying on business in Hong Kong as 國控股份有限公司)
(Stock Code: 01099)

ANNOUNCEMENT PRINCIPAL UNAUDITED FINANCIAL DATA OF CNMDC FOR THE THREE MONTHS ENDED 31 MARCH 2026

This announcement is made pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

Reference is made to the overseas regulatory announcement dated 23 April 2026 (the “**Announcement**”) issued by Sinopharm Group Co. Ltd. (the “**Company**”) in relation to the unaudited consolidated balance sheet, income statement and cash flow statement, and the unaudited balance sheet, income statement and cash flow statement of China National Medical Device Co., Ltd. (中國醫療器械有限公司)(“**CNMDC**”), a subsidiary of the Company, for the three months ended 31 March 2026 (the “**Reporting Period**”) issued by CNMDC on the websites of China Money and Shanghai Clearing House.

The board of directors of the Company would like to draw the attention of its shareholders and the public investors to the following principal unaudited financial data of CNMDC for the three months ended 31 March 2026 as set out in the Announcement.

** The Company is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance under its Chinese name and the English name “Sinopharm Group Co. Ltd.”.*

PRINCIPAL UNAUDITED FINANCIAL DATA OF THE CONSOLIDATED FINANCIAL STATEMENTS

Unit: Yuan
Currency: RMB

	The Reporting Period	Same period of last year	Changes of the Reporting Period over the same period of last year
Revenue	16,999,533,955.95	16,792,215,492.04	1.23%
Operating profit	220,193,989.50	276,670,003.14	-20.41%
Total comprehensive income attributable to owners of the parent company	115,145,211.10	124,439,512.66	-7.47%
Net cash flow arising from operating activities	-4,569,040,992.01	-3,132,381,711.35	45.86%
	At the end of the Reporting Period	At the beginning of the Reporting Period	Changes of the end of the Reporting Period over the beginning of the Reporting Period
Total assets	59,490,421,028.73	57,302,220,888.25	3.82%
Total equity attributable to owners of the parent company	8,415,197,366.46	8,300,052,155.36	1.39%

By order of the Board
Sinopharm Group Co. Ltd.
Jin Bin
Chairman

Shanghai, the PRC
23 April 2026

As at the date of this announcement, the executive Directors are Mr. Lian Wanyong and Mr. Yang Binghua; the non-executive Directors are Mr. Jin Bin, Mr. Chen Qiyu, Mr. Zu Jing, Mr. Xing Yonggang, Mr. Ma Yue, Mr. Chen Yuqing, Mr. Wen Deyong and Ms. Li Ying; and the independent non-executive Directors are Mr. Li Peiyu, Mr. Wu Tak Lung, Mr. Yu Weifeng, Mr. Shi Shenghao and Mr. Chen Weiru.